Analytical Method Validation
Rigorous validation of analytical methods for vaccines and immunologics to meet FDA, ICH Q2(R1), and global regulatory standards, ensuring data integrity and submission readiness across all critical quality attributes.
Navigating CMC regulatory requirements for vaccines and immunologics demands precision, compliance expertise, and deep scientific knowledge. VuRoyal Pharmaceutical delivers end-to-end CMC testing and regulatory support—from analytical method validation to submission-ready documentation—helping sponsors meet FDA, ICH, and global agency standards with confidence and speed.
Comprehensive CMC testing and regulatory support tailored for vaccine and immunologic product development and submission.
Rigorous validation of analytical methods for vaccines and immunologics to meet FDA, ICH Q2(R1), and global regulatory standards, ensuring data integrity and submission readiness across all critical quality attributes.
ICH-aligned stability studies for vaccine and immunologic formulations, including real-time and accelerated protocols, to support shelf-life determination and regulatory filing requirements.
Expert preparation of CMC sections for IND, BLA, NDA, and IMPD submissions, including quality dossiers, batch records, and specification documentation aligned with FDA and EMA expectations.
Comprehensive characterization and qualification of reference standards for vaccines and immunologics, ensuring traceability and compliance with pharmacopeial and regulatory agency requirements.
Quantitative potency assays and purity assessments for vaccine antigens and immunologic products, delivering reliable, reproducible data to support lot release, comparability, and regulatory submissions.
End-to-end analytical testing support for clinical-stage vaccine programs, covering release testing, comparability studies, and method transfers to ensure regulatory-compliant trial conduct.
We begin with an in-depth consultation to understand your vaccine or immunologic program, regulatory targets (FDA, EMA, ICH), and timeline. Our Ph.D.-level experts assess your CMC data gaps and define a precise testing and documentation scope tailored to your submission strategy.
See how VuRoyal has helped clinical sponsors and vaccine developers navigate CMC compliance with confidence.
We bring decades of pharmaceutical R&D expertise and full regulatory compliance to every CMC testing engagement.
Our Ph.D.-led team has decades of pharmaceutical R&D experience, ensuring your CMC package meets FDA and global agency standards.
As an FDA-registered, Massachusetts-approved pharmaceutical entity, we operate under rigorous quality management standards that regulators trust.
Headquartered in Boston with established networks across the U.S., China, and global markets, we support multi-regional regulatory submissions seamlessly.
From analytical testing and method validation to full CMC dossier preparation, our cost-optimized single-source model eliminates coordination gaps and accelerates timelines.
Pharmaceutical experts dedicated to advancing vaccine regulatory science.
Chief Executive Officer, Ph.D., MPA
Dr. Hao Wang leads VuRoyal Pharmaceutical as Chief Executive Officer, bringing a distinguished academic background—holding both a Ph.D. and a Master of Public Administration—alongside deep operational expertise in pharmaceutical R&D and regulatory affairs. He has been a recognized voice in vaccine science, having moderated high-profile scientific forums on vaccine adjuvants, including VuRoyal's inaugural QS-21 Forum in Shanghai in 2024 and the 2nd Online Technology Forum on Novel Vaccine Adjuvants in 2025. Under his leadership, VuRoyal secured an exclusive partnership with Desert King International in China, achieved key regulatory milestones for pharmaceutical excipient registration, and established the company as a trusted partner for CMC regulatory testing, clinical trial support, and vaccine adjuvant supply across global markets.
CMC regulatory requirements govern the chemistry, manufacturing, and controls of a drug or biologic product. For vaccines and immunologics, the FDA requires detailed characterization of the active substance, formulation, manufacturing process, analytical controls, and stability data. These requirements are outlined in 21 CFR Part 610, ICH Q6B, and applicable FDA guidance documents for biologics license applications (BLAs) and INDs.
Speak with our regulatory experts for a tailored consultation on your vaccine or immunologic program.
VuRoyal delivers CMC regulatory testing support to vaccine developers and sponsors across the U.S., China, and international markets.
Boston, MA
Headquarters
U.S., China & Global
Markets Served
Multi-Regional Support
Availability
Contact our team to discuss how we can support your CMC regulatory needs wherever you operate.
Recognized federal registration as a compliant pharmaceutical wholesaler
Certified under drug business quality management standards for compliant operations
All testing and distribution activities conducted under GMP-compliant quality frameworks
Submit your inquiry and a VuRoyal CMC expert will reach out to discuss your vaccine or immunologic testing and regulatory submission needs. We respond promptly to all inquiries from clinical sponsors, vaccine developers, and research organizations worldwide.
For immediate assistance, feel free to give us a direct call at +1 617-870-2690 You can also send us a quick email at
For immediate assistance, feel free to give us a direct call at +1 617-870-2690 You can also send us a quick email at